Bicyclic Ether O-GlcNAcase Inhibitors for Selective Tau Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Developing selective inhibitors for O-GlcNAcase to treat Alzheimer's disease and related tauopathies is challenging due to the non-specific inhibition of functionally related enzymes, leading to complex phenotypes.
Innovation Solution
Development of bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors, represented by specific structural formulas, to selectively inhibit O-GlcNAcase and modulate O-GlcNAc levels, thereby reducing tau hyperphosphorylation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective inhibitors are used to block O-GlcNAcase function, then inhibition of O-GlcNAcase is achieved, but lysosomal beta-hexosaminidases are also inhibited leading to complex phenotypes
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features (bicyclic ether core structure with particular substituent patterns) that confer selective binding to O-GlcNAcase active site while avoiding interaction with lysosomal beta-hexosaminidases. The compounds contain specific structural elements (Ar group, Y1/Y2 configurations, Z linker) that are tailored to match the spatial and chemical characteristics of the O-GlcNAcase binding pocket, thereby achieving local specificity at the enzyme-inhibitor interface.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters of the inhibitor structures (substituent types on Ar group, positions of Y1 and Y2, nature of Z linker, chain length of R groups) to optimize selectivity for O-GlcNAcase. By adjusting these chemical parameters, the inhibitors achieve differential binding affinities across the glycosidase enzyme family, enhancing selectivity while maintaining potent inhibition of the target enzyme.
2Reliability
If existing beta-N-acetylglucosaminidase inhibitors are used, then O-GlcNAcase inhibition is achieved, but potency and selectivity are insufficient
Solution Approach 1:
The patent applies composite materials by creating inhibitor molecules that combine multiple functional moieties into a unified structure: a bicyclic ether core (providing structural rigidity and target recognition), aromatic substituents (Ar group for pi-stacking interactions), and tailored side chains (R groups for hydrophobic and hydrogen bonding interactions). This composite molecular architecture achieves superior binding affinity and selectivity compared to simpler inhibitor structures, thereby reducing the concentration required for effective inhibition.
Solution Approach 2:
The patent incorporates dynamics by designing inhibitors with flexible side chains (variable R groups and linkers) that can adapt to the binding pocket conformation of O-GlcNAcase. The molecular structure allows for conformational adjustment upon binding, optimizing interactions with key residues in the active site. This dynamic adaptability enhances binding affinity and selectivity, reducing the inhibitor concentration needed for effective enzyme blockade.
Data Source
AI summary
Described herein are compounds represented by formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of preparing and using the same. The variables Ar, X, R1, R3, R4, Y1, Y2, n and p are as defined herein.